慢性乙型肝炎新型免疫治疗研究进展

Recent progress on novel immunotherapy in the treatment of chronic hepatitis B

慢性乙型肝炎(CHB)仍然是世界公共卫生问题之一,其持续进展可引起肝硬化和肝细胞癌(HCC),甚至最终导致死亡。目前抗病毒药物能够抑制乙型肝炎病毒(HBV)DNA复制并减少肝脏炎症,可以逆转肝纤维化及降低肝硬化、HCC的风险,但仍难以实现CHB的完全治愈,并且停止治疗后常出现复发。免疫治疗能够打破CHB患者对HBV的免疫耐受及恢复对HBV的免疫应答,有效的免疫治疗策略配合抗病毒药物有望实现CHB的治愈。

Chronic hepatitis B(CHB)is still a public healthy problem all over the world,its consistent development can cause liver cirrhosis,hepatocellular carcinoma(HCC)and even death.At present,antiviral drugs can repress the replication of hepatitis B virus(HBV)DNA,reduce liver inflammation,reverse liver fibrosis and decreased the risk of cirrhosis and HCC.But it is still difficult to completely cure CHB,and the recurrence of virus is common after termination of treatment.Immunotherapy can break the immune tolerance and restore their immune response to HBV in CHB patients,and effective strategies of immunotherapy combined with direct antiviral drugs are expected to achieve the cure of CHB.